[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558901":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":118,"collaborators":10,"id":120,"slug":121,"hasResults":122,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":10,"eligibilityCriteria":126,"healthyVolunteers":122,"sex":127,"minAge":128,"maxAge":10,"enrollmentInfo":129,"targetDuration":10,"studyType":132,"phases":10,"briefSummary":133,"conditions":134,"keywords":141,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Biopsy-proven ER+ Metastatic Invasive Lobular Carcinoma\u002FILC",null,"Participants will have biopsy-proven metastatic ILC, confirmed ER+ breast cancer",[13],"Diagnostic Test: 18F-Fluoroestradiol PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","18F-Fluoroestradiol PET\u002FCT","Scanned at baseline and again posttreatment within 2 weeks of the restaging FDG PET\u002FCT",[9],[21],"FES PET\u002FCT",[23],{"name":24,"affiliation":5,"role":25},"Somali Gavane, MD","PRINCIPAL_INVESTIGATOR",[27,31],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":30},"CONTACT","212-639-2403","GavaneS@mskcc.org",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Komal Jhaveri, MD","646-888-5145","jhaverik@mskcc.org",[36,52,63,74,86,97,107],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)","RECRUITING","Basking Ridge","New Jersey","07920","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-74.54932,40.70621,{"lat":48,"lon":47},[51],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":10},{"facility":53,"status":38,"city":54,"state":40,"zip":55,"country":42,"countryCode":43,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Memorial Sloan Kettering Monmouth (Limited protocol activities)","Middletown","07748",{"type":45,"coordinates":57},[58,59],-74.11709,40.39428,{"lat":59,"lon":58},[62],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":10},{"facility":64,"status":38,"city":65,"state":40,"zip":66,"country":42,"countryCode":43,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Memorial Sloan Kettering Bergen (All Protocol Activities)","Montvale","07645",{"type":45,"coordinates":68},[69,70],-74.02292,41.04676,{"lat":70,"lon":69},[73],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":10},{"facility":75,"status":38,"city":76,"state":77,"zip":78,"country":42,"countryCode":43,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Memorial Sloan Kettering Suffolk-Commack (All protocol activity)","Commack","New York","11725",{"type":45,"coordinates":80},[81,82],-73.29289,40.84288,{"lat":82,"lon":81},[85],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":10},{"facility":87,"status":38,"city":88,"state":77,"zip":89,"country":42,"countryCode":43,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Memorial Sloan Kettering Westchester (Limited Protocol Activities)","Harrison","10604",{"type":45,"coordinates":91},[92,93],-73.71263,40.96899,{"lat":93,"lon":92},[96],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":10},{"facility":98,"status":38,"city":77,"state":77,"zip":99,"country":42,"countryCode":43,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)","10065",{"type":45,"coordinates":101},[102,103],-74.00597,40.71427,{"lat":103,"lon":102},[106],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":10},{"facility":108,"status":38,"city":109,"state":77,"zip":110,"country":42,"countryCode":43,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Memorial Sloan Kettering Nassau (Limited Protocol Activites)","Rockville Centre","11553",{"type":45,"coordinates":112},[113,114],-73.64124,40.65871,{"lat":114,"lon":113},[117],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":10},{"type":119,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100558901","a-study-comparing-cancer-imaging-approaches-in-people-with-lobular-breast-cancer-100558901",false,"NCT06557148","A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer","18F-Fluoroestradiol (FES) Positron Emission Tomography for the Detection and Treatment Response Monitoring in Patients With Metastatic Lobular Breast Carcinoma","Inclusion Criteria:\n\n* Adult patient \\> 18 years old\n* Biopsy-proven metastatic ILC\n* Confirmed ER+ breast cancer from either primary tumor or metastatic biopsy (ER receptor percent staining ≥ 10% of tumor cells by IHC)\n* HER2-negative per ASCO\u002FCAP\n* ECOG Performance Status Score of 0, 1 or 2.\n* Patient can have received up to 2 lines of therapy in the metastatic setting\n* Life expectancy of at least 12 months\n\nExclusion Criteria:\n\n* Low ER expression defined as ER \\\u003C10% of tumor cells by IHC\n* Patients who have been on adjuvant ER-blocking endocrine therapy with SERM or SERD without an 8- and 24-weeks washout, respectively. (The use of aromatase inhibitors or ovarian suppression is permitted given that they do not block estrogen receptors).\n* Pregnancy or lactation or parturient or nursing mother\n* Patient presents with any other clinically active, serious, life-threatening disease, medical, or psychiatric condition, and\u002For who has a life expectancy of \\\u003C12 months, or for whom study participation may compromise their management; and\u002For a patient who the investigator judges to be unsuitable for participation in the study for any reason.","ALL","18 Years",{"count":130,"type":131},30,"ESTIMATED","OBSERVATIONAL","The purpose of this study to compare two types of cancer imaging scans to see which is better at detecting and monitoring metastatic ILC. This study will compare PET\u002FCT (positron emission tomography\u002Fcomputed tomography) scans using the radiotracer fluorine 18 (18F)-fluoroestradiol (FES) with a standard imaging approach for detecting and monitoring ILC, PET\u002FCT scans using the radiotracer 18F-fluorodeoxyglucose (FDG). These scans will be referred to as FES PET\u002FCT scans and FDG PET\u002FCT scans.",[135,136,137,138,139,140],"Breast Cancer","Lobular Breast Carcinoma","Breast Carcinoma","Metastatic Breast Cancer","Metastatic Lobular Breast Carcinoma","Metastatic Breast Carcinoma",[142,143,144,145,146,147,148,149,150,5],"breast cancer","lobular breast cancer","lobular breast carcinoma","breast carcinoma","metastatic breast cancer","metastatic lobular breast cancer","metastatic lobular breast carcinoma","metastatic breast carcinoma","24-134","2026-02-25",{"date":153,"type":154},"2026-02-27","ACTUAL",{"date":156,"type":154},"2024-08-13",{"date":158,"type":131},"2027-08-13",{"name":5,"class":6},7]